Registry Study Linking MammaPrint, BluePrint, and Full-Genome Data to Clinical Information in Stage I-III Breast Cancer Patients
Led by Agendia · Updated on 2025-08-20
30000
Participants Needed
134
Research Sites
34 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting the FLEX Registry, a large-scale, population-based study focusing on patients with stage I to III breast cancer who have undergone MammaPrint and BluePrint testing on their primary breast tumors. This observational registry aims to gather comprehensive full genome expression data linked with clinical information to explore new gene associations that may have prognostic or predictive value. The design is adaptive, allowing additional targeted substudies and arms to be added over time for more specific investigations.
All participants will have their tumor samples tested using MammaPrint and BluePrint through the full-genome testing array provided by Agendia. Treatment decisions are made by the treating physician following NCCN guidelines or recognized alternatives, with no specific treatment mandated by the study. The registry plans to enroll about 30,000 patients from more than 125 US institutions, encompassing various treatment arms detailed in study appendices.
Participants will have clinical data collected online at multiple time points at enrollment, during treatment, and at 1, 3, 5, and 10 years after diagnosis. This long-term follow-up allows researchers to study gene expression alongside clinical outcomes, supporting the creation of subgroup analyses and future targeted trials. The primary outcomes include establishing a large-scale full genome expression registry and providing infrastructure for examining smaller patient groups over the 10-year study period.
CONDITIONS
Brief Title
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Research Team
M
Michelle Landon, MS, CGC
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patients with stage I, II, or III breast cancer who have received MammaPrint testing, with or without BluePrint
Male or female patients
Signed informed consent form on or before enrollment
New primary breast lesion
You will not qualify if you...
Tumor sample with 30% or fewer tumor cells or failing quality assurance or quality control criteria
Presence of metastatic disease
Recurrent breast cancer
Stage 0 breast cancer
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - At enrollment
Participants undergo MammaPrint, BluePrint, and full-genome testing to collect genetic expression data.
1 visit (in-person)
Long-term Monitoring
Duration - Up to 10 years
Participants are observed through clinical data collection at enrollment, during treatment, and at multiple time points post diagnosis to evaluate gene associations and outcomes.
Visits at enrollment, time of treatment, and at 1, 3, 5, and 10 years post diagnosis
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Studying Key Non-coding RNAs and Their Interaction With Chromatin Remodeling in Breast Cancer Patients
Comparing 18F-FDG and 68Ga-FAPI-46 PET Scans in Women With ER-positive Breast Cancer
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Observational Study Comparing 3D and 2D Echocardiography for Early Heart Damage Detection in Patients Receiving Anthracyclines and HER2-Targeted Cancer Therapies
Study Comparing 3D-Printed Biodegradable Breast Implants, Traditional Breast-Conserving Surgery, and Silicone Implant Reconstruction for Breast Cancer Patients
Ultrahypofractionated 5-Session Whole Breast Radiotherapy with Boost versus Standard 15-Session Radiotherapy for Breast Cancer Patients with Unfavorable Characteristics
Phase II Study Comparing 5-Day vs. 9-Day Whole Breast Radiotherapy with Boost in Early-stage Breast Cancer
Evaluating 68Ga-FAPI PETCT for Checking Axillary Lymph Node Status After Neoadjuvant Therapy in Women with Breast Cancer
PETCT Imaging Using 68Ga-RM26-RGD to Detect Breast, Brain, and Prostate Tumors with GRPR and v3 Receptors
Exploratory Study of 68Ga-SorB PETCT Imaging to Diagnose Sortilin-Positive Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Prediction of Anthracycline Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study.
Joyce O'Shaughnessy, Adam M Brufsky, Rakhshanda Layeequr Rahman...